Hyperimmune Globulins in COVID-19.

Area of Science:

• Immunology
• Virology
• Therapeutics

Background:

• The COVID-19 pandemic necessitated novel therapeutic strategies due to the lack of proven treatments.
• COVID-19 convalescent plasma (CCP) showed initial promise but had variable efficacy tied to antibody titers.
• Hyperimmune immunoglobulins (hIG) emerged as a purified alternative derived from CCP.

Purpose of the Study:

• To evaluate the efficacy and potential of hyperimmune immunoglobulins (hIG) as a COVID-19 therapy.
• To compare hIG with placebo and CCP, considering factors influencing its effectiveness.
• To explore advantages of hIG over CCP and future production strategies.

Main Methods:

• Purification of hIG from CCP units via stringent chromatographic processing.
• Clinical trials assessing outcomes at day 28 compared to placebo or CCP.
• Analysis of factors contributing to hIG efficacy variability.

Main Results:

• hIG likely improved outcomes compared to placebo or CCP at day 28, especially in unvaccinated patients.
• Efficacy was influenced by assessment timing, hIG dose, patient immunity, and viral variant matching.
• hIG offers advantages in administration and variant-specific preparations over CCP.

Conclusions:

• hIG presents a viable therapeutic option for COVID-19, with potential benefits over CCP.
• Further studies are needed, particularly in immunocompromised and persistently infected patients.
• Developing infrastructure for large-scale, plasma-independent hIG production is crucial for future pandemic preparedness.